Dimitri Mandolesi

increased size of third ventricle in patients with multiple sclerosis and chronic cerebrospinal venous insufficiency

Objective: The aim of the present study was to assess the size of the third ventricle in a sample of patients with multiple sclerosis (MS) affected by chronic cerebrospinal venous insufficiency (CCSVI), versus size of the third ventricle in a healthy control group. Background: CCSVI, a new nosological vascular pattern, has recently been associated with MS. Methods: We enrolled 33 patients affected by MS (three in the primary progressive clinical course, 23 in the relapsing–remitting clinical course, and seven in the secondary–progressive clinical course). All patients had been affected by CCSVI and were tested using an echo color Doppler (ECD) imaging unit. The group of 33 affected by both MS and CCSVI (MS–CCSVI) was composed of 19 females and 14 males with a mean age of 40±10 years, from a minimum age of 20 years to a maximum age of 66 years, with a median of 40 years and a mode of 32 years. We compared the 33 MS–CCSVI patients with 33 healthy control subjects of similar sex and age. In the MS–CCSVI group, the MS clinical severity was expressed by expanded disability status scale (EDSS) score: light (19 patients, scoring 1, 2, or 3); medium (ten patients with a score of 4, 5, or 6), and severe (four patients with a score of 7, 8, or 9). The average duration of the MS was 10±7 years (from a minimum of 1 to a maximum of 26 years, with a median of 10 years and a mode of 1 year). Results: In the MS–CCSVI group, the third ventricle diameter was 6.2±1.7 mm (from a minimum of 2.5 mm to a maximum of 9.2 mm, with a median of 6.3 mm, and a mode of 6.0 mm). Our data showed that 29 patients (88%) had an increase in third ventricle diameter, whereas only four patients (12%) had physiological size (less than 4 mm) comparable to all healthy control group subjects (27.28%). These results show that the increase in the third ventricle diameter could represent a criterion of positivity of neurological disease in patients with CCSVI.

Using the MEM-net program to report on mapping the EchoColorDoppler assessment for chronic cerebro spinal venous insufficiency

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Journal of Vascular Diagnostics 2014:2 59–66 Journal of Vascular Diagnostics Dovepress

Chronic muscular Pain treatment with Muscular Acoustic Modulator Device in elderly

Background Muscles Contractures are an important part of multi-factorial etiology of chronic pain. MAM® is an acoustic waves device modulated in power and frequency (0-50 Hz, 0-5 Bar) for treatment of muscular contractures. If the treatment of the chronic muscular contractures with MAM® can improve quality life in elderly.

Breath test for o.s.s. detection in humans compared to free radical analysis in blood

A laser sensor realised at ENEA Frascati (Italy) based on photoacoustic spectroscopy (PAS), able to detect gas concentrations down to sub-ppb level, was applied for revealing ethylene traces emitted in the exhaled breath by human subjects, before as well as after an antioxidant treatment. In the present work, the changes in breath ethylene detected by PAS, compared to a direct analysis of reactive oxygen species detected in the blood by a spectrophotometric method (d- ROMs), were investigated in each patient. The sensorial system, the methods, the experiment and the results are discussed in the paper.